Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P.
Papaldo P, et al. Among authors: di cosimo s, di lauro l.
J Clin Oncol. 2003 Sep 15;21(18):3462-8. doi: 10.1200/JCO.2003.03.034.
J Clin Oncol. 2003.
PMID: 12972521
Clinical Trial.